ELTP (Elite Pharmaceuticals) Institutional Ownership: 0.05% (As of Jul. 07, 2026)


ELTP Elite Pharmaceuticals Inc ELTP
55 GF Score
Price $0.36
GF Value $0.56
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Elite Pharmaceuticals Institutional Ownership?

Elite Pharmaceuticals ELTP +0.26% 55 Institutional Ownership is 0.05% as of Jul. 07, 2026. GuruFocus rates ELTP with a GF Score™ of 55/100 and a GF Value™ of $0.56 (Possible Value Trap). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Elite Pharmaceuticals's institutional ownership is 0.05%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Elite Pharmaceuticals's Insider Ownership is 10.71%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Elite Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 77.99%.

Elite Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals Institutional Ownership Chart

Elite Pharmaceuticals Historical Data

The historical data trend for Elite Pharmaceuticals can be seen below:

2020-11-30 2020-12-31 2021-01-31 2021-02-28 2021-04-30 2021-05-31 2021-06-30 2021-07-31 2021-08-31 2021-09-30
Institutional Ownership 0.07 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
ELTP
55GF Score
Elite Pharmaceuticals Inc ELTP
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elite Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.05% mean?
Elite Pharmaceuticals (ELTP) has a Institutional Ownership of 0.05% as of Jul. 07, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Elite Pharmaceuticals and its competitors.
Is Elite Pharmaceuticals' Institutional Ownership too high?
Elite Pharmaceuticals' current Institutional Ownership is 0.05%. Overall, Elite Pharmaceuticals has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Institutional Ownership compare to EBS and NIKA?
Elite Pharmaceuticals' Institutional Ownership of 0.05% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current Institutional Ownership is 0.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.56, compared to a current price of $0.36 — trading 35.5% below its estimated fair value. The current Institutional Ownership is 0.05%. Elite Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Institutional Ownership is 0.05% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.36 is trading 35.5% below its estimated GF Value™ of $0.56. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

  • Institutional Ownership: 0.05%
  • GF Value™: $0.56 vs. price of $0.36 (35.5% below fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
55GF Score

Get the complete analysis for ELTP

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.36
Price
$0.56
GF Value